These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21431636)

  • 21. Molecular cytogenetics.
    Kearney L
    Best Pract Res Clin Haematol; 2001 Sep; 14(3):645-69. PubMed ID: 11640874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
    Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
    Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic role of conventional cytogenetics and fluorescence in situ hybridization (FISH) in chronic myeloid leukemia patients.
    Jha CB; Kucheria K; Choudhary VP
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):171-5. PubMed ID: 18603893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metaphase cytogenetic techniques in multiple myeloma.
    Sawyer JR
    Methods Mol Biol; 2011; 730():149-58. PubMed ID: 21431640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytogenetic study of 121 patients suffering from various hematologic neoplasms using the in situ hybridization technique].
    Pérez Losada A; Solé F; Woessner S; Florensa L; Besses C; Espinet B; Caballín MR; García Eroles L; Sans-Sabrafén J
    Sangre (Barc); 1996 Jun; 41(3):201-9. PubMed ID: 8755208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics.
    Gerr H; Gadzicki D; Kreipe H; Schlegelberger B; Wilkens L
    Pathobiology; 2006; 73(6):271-9. PubMed ID: 17374964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular diagnosis of myeloproliferative neoplasms.
    Patnaik MM; Tefferi A
    Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.
    Duckworth CB; Zhang L; Li S
    Int J Clin Exp Pathol; 2014; 7(2):801-7. PubMed ID: 24551307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH).
    Decamp M; Klein E; Godon C; Lestringant V; Roynard P; Theisen O; Jimenez-Pocquet M; Roche-Lestienne C; Bidet A; Veronese L
    Curr Res Transl Med; 2023; 71(4):103424. PubMed ID: 38011761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD
    Clin Haematol; 1980 Feb; 9(1):159-74. PubMed ID: 6768481
    [No Abstract]   [Full Text] [Related]  

  • 32. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
    Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
    Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular cytogenetics in metaphase and interphase cells for cancer and genetic research, diagnosis and prognosis. Application in tissue sections and cell suspensions.
    Mühlmann M
    Genet Mol Res; 2002 Jun; 1(2):117-27. PubMed ID: 14963837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms.
    Spanoudakis E; Bazdiara I; Pantelidou D; Kotsianidis I; Papadopoulos V; Margaritis D; Xanthopoulidis G; Moustakidis E; Mantzourani S; Bourikas G; Tsatalas C
    Leuk Res; 2011 Apr; 35(4):459-64. PubMed ID: 20828816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cytogenetic and molecular cytogenetic studies on hematologic malignancies.
    Kolialexi A; Tsangaris GT; Kitsiou S; Kanavakis E; Mavrou A
    Anticancer Res; 2005; 25(4):2979-83. PubMed ID: 16080555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies.
    Tefferi A; Nicolosi M; Penna D; Vallapureddy R; Hanson CA; Pardanani A; Gangat N; Ketterling RP
    Leukemia; 2019 Oct; 33(10):2522-2553. PubMed ID: 31040370
    [No Abstract]   [Full Text] [Related]  

  • 38. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
    Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders.
    Kussick SJ; Wood BL
    Am J Clin Pathol; 2003 Dec; 120(6):854-65. PubMed ID: 14671974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosome Preparation for Myeloid Malignancies.
    Hui EK; Wan TS; Ng MH
    Methods Mol Biol; 2017; 1541():11-17. PubMed ID: 27910010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.